Frontlight ResearchEarly access
CompletedPhase 1
A Phase 1, First-in-human Study of VX-668
Key facts
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Where
- Gainesville, Lenexa, Orlando, Salt Lake City, and Tempe, United StatesSee the 5 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 114 people enrolled
- Started
- 8 Feb 2023
- Ended
- 13 Feb 2024
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- VX-668
- Placebo
- Record updated
- 15 March 2024
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participants of age between 18 to 55 years (inclusive)
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
- A total body weight of more than (>)50 kg
- Nonsmoker or ex-smoker for at least 3 months before screening
Who cannot take part
- Any condition possibly affecting drug absorption
- Females of childbearing potential; Other protocol defined Inclusion/Exclusion criteria may apply
Where in United States
- University of FloridaGainesville, United States
- ICON LenexaLenexa, United States
- Central Florida Pulmonary Group, P.A.Orlando, United States
- ICON-Salt Lake CitySalt Lake City, United States
- Celerion - TempeTempe, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.
The 4 groups in the trial
- Part ATreatment being tested
Participants grouped in different cohorts will receive a single ascending dose of VX-668.
Treatment: VX-668
- Placebo Part APlacebo, for comparison
Participants will be randomized to receive placebo matched to VX-668.
Treatment: Placebo
- Part BTreatment being tested
Participants grouped in different cohorts will receive multiple doses of VX-668.The dose levels will be determined based on the data from Part A.
Treatment: VX-668
- Placebo Part BPlacebo, for comparison
Participants will be randomized to receive placebo matched to VX-668.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668
- Record updated
- 15 March 2024